Receptor expression, cytogenetic, and molecular analysis of six continuous human glioma cell lines

In Vitro Cell Dev Biol Anim. 1998 Jun;34(6):455-62. doi: 10.1007/s11626-998-0078-x.


Six human glioma cell lines were established from tissues obtained from five patients diagnosed with Kernohan grade IV glioblastoma multiforme and one from a patient with a grade II astrocytoma. One line was from a recurrent patient who had received prior therapy; the other lines were derived from patients at initial diagnosis and/or before cytoreductive therapies other than surgery were given. Considerable variability in phenotypic, karyotypic, and cell surface marker expression was displayed between the six human glioma cell lines. The karyotypes ranged from apparently normal (grade II astrocytoma) to those with complex rearrangements. Trisomy of chromosome 7 was the most common abnormality. The extensive cytogenetic and molecular characterization of these lines may facilitate their utilization in cellular and molecular biologic studies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Animals
  • Astrocytoma / classification
  • Astrocytoma / genetics
  • Astrocytoma / metabolism
  • Astrocytoma / pathology
  • Biomarkers, Tumor / metabolism
  • Brain Neoplasms* / classification
  • Brain Neoplasms* / genetics
  • Brain Neoplasms* / metabolism
  • Brain Neoplasms* / pathology
  • DNA, Neoplasm / analysis
  • Female
  • Glioblastoma* / classification
  • Glioblastoma* / genetics
  • Glioblastoma* / metabolism
  • Glioblastoma* / pathology
  • Humans
  • Immunoenzyme Techniques
  • In Situ Hybridization, Fluorescence
  • Karyotyping
  • Male
  • Middle Aged
  • Polymerase Chain Reaction
  • Receptors, Platelet-Derived Growth Factor / metabolism
  • Transforming Growth Factor beta / analysis
  • Tumor Cells, Cultured


  • Biomarkers, Tumor
  • DNA, Neoplasm
  • Transforming Growth Factor beta
  • Receptors, Platelet-Derived Growth Factor